Drug Trial Radar · NCT04001517
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
Last checked: Nov 19, 2026Latest source record: Jun 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Sep 30, 2019
Primary completion
Jun 30, 2020
Study completion Jun 30, 2020
Sponsor
- Lead sponsor
- EIP Pharma IncIndustry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials
- First posted
- Jun 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1) administered with food for 16 weeks in subjects with DLB. The primary objective is to evaluate the effect of neflamapimod on cognitive function as assessed in a study-specific Cogstate Neuropsychological Test Battery (NTB). Secondary endpoints include the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI-10), Timed Up and Go Test, and electroencephalogram (EEG) as a potential biomarker for DLB.
Conditions
- Dementia With Lewy Bodies (DLB)
Interventions
NeflamapimodDrug
Double-Blind, Placebo-Controlled
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite Z-score of a Study-specific Neuropsychological Test Battery (NTB) Including Tests From Cogstate Battery, Letter Fluency Test and Category Fluency TestTime frame: As the analysis was by Mixed Model for Repeated Measures, all time points at which NTB was assessed utilized in the analysis. The difference reported is the mean difference over the entire course of the study.
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
University of California San Diego (UCSD)
La Jolla, California
Pacific Neuroscience Institute
Santa Monica, California
University of Colorado
Aurora, Colorado
Elite Clinical Research
Miami, Florida
University of Kansas Medical Center
Kansas City, Kansas
Massachusetts General Hospital
Charlestown, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
Cleveland Clinic - Lou Ruvo Center for Brain Health
Las Vegas, Nevada
New York Presbyterian Hospital - Columbia University Medical Center
New York, New York
University of Rochester
Rochester, New York
University of North Carolina
Chapel Hill, North Carolina
Cleveland Clinic
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Summit Research Network
Portland, Oregon
Oregon Health & Science University
Portland, Oregon
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Virginia
Charlottesville, Virginia
National Clinical Research, Inc.
Richmond, Virginia
Northwest Clinical Research Center
Bellevue, Washington
University of Washington
Seattle, Washington
Inland Northwest Research
Spokane, Washington
Brain Research Center
's-Hertogenbosch, Netherlands
Brain Research Center
Amsterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.